Freeze-and-immune combo targets tough sarcomas
NCT ID NCT07602049
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether freezing tumors (cryoablation) combined with an immunotherapy drug (camrelizumab) can shrink advanced soft tissue sarcomas that have stopped responding to standard treatments. About 57 participants aged 14 to 70 will receive this combination. The main goal is to see how many patients experience significant tumor shrinkage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-Sen Univerisity
RECRUITINGGuangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a Patient's own immune cells fight advanced sarcoma?
- Can a targeted pill stall advanced sarcomas?
- Smartwatch exercise plan aims to rebuild fitness in young cancer survivors
- Can two drugs together fight Hard-to-Treat bone and Soft-Tissue cancers?
- Can tailored exercise help young sarcoma survivors recover strength?